Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | APP | P05067 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002746 | 0.79 | KCNH2 (0.35) | — | |
| SCHEMBL3009508 | 0.73 | KCNH2 (0.68) | ALDH1A1SMN1; SMN2KDM4EHSD17B10LMNA | |
| SCHEMBL9528495 | 0.71 | APP (0.66) | L3MBTL1ALDH1A1APP | |
| SCHEMBL4981287 | 0.69 | L3MBTL1 (0.57) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EAPP | |
| SCHEMBL6816262 | 0.69 | L3MBTL1 (0.60) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EAPP | |
| SCHEMBL7570603 | 0.69 | L3MBTL1 (0.56) | L3MBTL1ALDH1A1SMN1; SMN2APPTSHR | |
| SCHEMBL9310449 | 0.68 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1KDM4EHSD17B10APP | |
| SCHEMBL14107981 | 0.68 | L3MBTL1 (0.59) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EAPP | |
| SCHEMBL9312413 | 0.67 | L3MBTL1 (0.65) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EHSD17B10 | |
| SCHEMBL5824190 | 0.67 | L3MBTL1 (0.57) | L3MBTL1ALDH1A1SMN1; SMN2KDM4EAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2144915-B1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | ESTEVE LABOR DR (ES) | 2014-03-19 | — | — | EP | disclosed |
| EP-2144915-B1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | ESTEVE LABOR DR (ES) | 2014-03-19 | — | — | EP | disclosed |
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL. DR. ESTEVE, S.A. (ES) | 2010-08-05 | — | — | US | disclosed |
| EP-2144915-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008125349-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008125349-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2008-10-23 | — | — | WO | disclosed |
| EP-1982987-A1 | Spiro-pyrano-pyrazole derivatives | Laboratorios del Dr. Esteve S.A. (ES) | 2008-10-22 | — | — | EP | disclosed |
| EP-1982987-A1 | Spiro-pyrano-pyrazole derivatives | Laboratorios del Dr. Esteve S.A. (ES) | 2008-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197714-A1 | SPIRO-PYRANO-PYRAZOLE DERIVATIVES | SIGMAR1, TMEM97, OPRD1 | L3MBTL1 4868/4885ALDH1A1 454/4885SMN1; SMN2 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.